Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous magnesium sulfate to prevent contrast-induced nephropathy in angiography patients
IRCT20250507065634N9Phase 3Completed
- Sponsor
- Shariati Hospital
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of magnesium sulfate in contrast-induced nephropathy (CIN), sponsored by Shariati Hospital. Started Jan 2026; status: completed.
02
Drugs
magnesium sulfate
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on IRCT20250507065634N9.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250507065634N9.